Remember to vote, #radonc ! 🗳️✅

astro.org/about-astro/go…

Congratulations David Kirsch, MD, PhD & team! Princess Margaret Cancer Centre Research Radiation Oncology

Further takeaways from the presentation:
🔵This study included patients with high risk disease- 79% T3-4, 85% N+
🔵median time to cCR= 6 months
🟢0% G3-4 Toxicity
☢️If there is local regrowth, CRT can still be used an organ preserving approach

#Cancerbreakthrough
#ASCO24

🚨HPV ctDNA detection at 3-months post-CRT for Anal Canal SCC is strongly prognostic of recurrence and outperforms clinicopathologic factors!

Provides clinical data to support future trial designs for HPV driven malignancy
#ASCO24

With ASTRO elections coming up this week, why do so many members think Neha Vapiwala deserves our vote to be the next President? For starters, former ASTRO presidents and gold medal winners have concurred she is one of the most inclusive and effective leaders to ever run for

TRANSMET: addition of liver transplant to chemo in CRC with unresectable liver mets: big OS benefit (5 yr 57% v 13%).

Curve plateauing at 5 years suggests ~1/2 pts can be cured!

Challenge is liver availability - on trial, prioritization < 2 mo after completing chemo.

#ASCO24

Congrats Monika Krzyzanowska , discussant for #ASCO REACH plenary talk. Early pall care, virtual visits 👌

Great lecture by Lillian Siu at #ASCO24
Nice summary of old observations mirrored to modern concepts - “Rear Mirror, Looking Glass”
Ending with few examples of continuous pursuit to advance cancer research and invest in the future - “Crystal Ball” 😊
#mentor
#cancerresearch

Yes!
Cant wait to see all the data! First RCT showing benefit of LT over C in selected population with unresectable LM Pål-Dag Line Arndt Vogel Grainne O'Kane

WOW!

HPV ctDNA detection at 3 months after dCRT for anal canal cancer associated with 100% risk of recurrence!

8% with HPV ctDNA negative

#ASCO24

🚨🚨ABC-07🚨🚨

Inoperable, locally advanced, cholangiocarcinoma

After 4c Gem-Cis, pts randomized to:

2c Gem-Cis (6 total) + RT (50 Gy/5 or 67.5/15)
vs.
4c Gem-Cis (8 total)

🟰 DFS 8.6 m vs. 9.0 m
✅ Suggestion of ⬆️ mOS with ☢️ (23.4 vs. 17.2 m)
#ASCO24

Pancreas RT: plot thickens w RTOG 0848 showing 5yr OS (48 v 29 mo) & DFS (47 v 19 mo) benefit to adjuvant chemoRT in resectable pancreas ca for pN0 subset.

My interpretation: N0 = have greater risk of local v distant recurrence – may benefit from locoregional tx. 1/3

#ASCO24

Support an Endowed ASCO YIA in #ProstateCancer in Honor of Dr. Felix Feng
Click to donate:
p2p.conquer.org/uniteandconque…

Laura Dawson Amir Safavi Sean McBride 1st research I ever did with Laura Dawson
redjournal.org/article/S0360-…

What an amazing Radiation Oncology STARS21 research day. Record attendance. 76 abstracts from rising stars! Outstanding research. Thanks to all presenters, supervisors, awardees, sponsors, staff, research team Shane Harding Princess Margaret Cancer Centre Research Sunnybrook Health Sciences Centre

Attending #ESTRO24 ?

There's an ASTRO #ESTRO24 joint session on Sunday focused on integrating #Radiopharmaceuticals into the cancer treatment pathway!

Stop by and ask us your questions!

While we will miss her energy and passion for science, we wish Dr. Karam all the best in her new position!

Karam named head of radiation oncology department medicine.wustl.edu/news/karam-nam… via @wustlmed

Statewide survey of PCPs & GI/hep providers on HCC surveillance practices in Digestive Diseases and Sciences

• Large gaps in HCC surveillance knowledge
• High interest in risk-stratification and patient navigation tools

link.springer.com/article/10.100…

Thanks to UNC Lineberger for the support!

Pre-transplant Use of Immune Checkpoint Inhibitors for HCC
American Journal of Transplantation
doi.org/10.1016/j.ajt.…
🔎 RWD🇨🇳, 83 pts
👉27.7% developed allograft rejection, mortality: 6/83
👉≥ 30 days before TX protective
🤔feasible, but relevant risk
ESMO - Eur. Oncology ILCA EASLnews #livertwitter

One week left to secure your spot at the #UofTDRO Alumni Reception during ESTRO! Space is limited, so act fast.Don't miss out—register by April 29th: bit.ly/48Sswdn
Laura Dawson